Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 龙虾 (Lobster) 龙虾 (Lobster) +29.51%
#3 MetaDAO MetaDAO +29.20%
#4 Rain Rain +24.16%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +19.73%
#6 Bedrock Bedrock +19.11%
#7 Pons Pons +17.61%
#8 Prom Prom +16.34%
#9 Humanity Humanity +14.45%
#10 Ontology Gas Ontology Gas +14.45%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Rank in Stocks #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$70.50
Last synced: 2025-11-14
Market Cap
$7.33B
Change (1 day)
0.00%
Change (1 year)
116.32%
Country
US
Trade Metsera, Inc. (MTSR)

Category

Healthcare
Revenue for Metsera, Inc. (MTSR)
Revenue in Aug 2026 TTM: 0
According to Metsera, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Metsera, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH